Skye Bioscience's obesity drug fails to meet main goal of mid-stage study
06/10/2025 12:08
Oct 6 (Reuters) - Skye Bioscience SKYE.O said on Monday its experimental obesity drug did not meet the main goal of a mid-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug